Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
GlaxoSmithKline Settles Most Zantac Lawsuits for $2.2B
The settlement, announced on Wednesday, resolves 93% of all Zantac cases in state courts against GlaxoSmithKline.
Drugmaker to settle nearly 80,000 Zantac lawsuits for up to $2.2 billion
UK-based pharmaceutical giant GSK, or GlaxoSmithKline, has announced that it has agreed to settle nearly 80,000 state-level Zantac cases. The lawsuits claimed that the now-discontinued version of the heartburn drug caused cancer,
GSK shares leap after drug firm settles US Zantac cancer claim lawsuit
GSK has always refuted claims that its discontinued heartburn drug had cancer-causing risks, arguing that expert testimonies were not reliable. View on euronews
GSK Shares Soar on $2.2B Zantac Lawsuit Settlement
Shares of the UK-based pharma giant GlaxoSmithKline PLC ($GB:GSK) soared over 6% after the company announced a settlement of up to $2.2 billion
GSK jumps 6% after $2.2B Zantac settlement: why analysts see more upside
GlaxoSmithKline (GSK) saw its shares jump more than 6% after the pharmaceutical giant announced a settlement of up to $2.2 billion (€2.01bn) to resolve tens of thousands of lawsuits in the US related to its discontinued heartburn medication, Zantac.
GSK Rises After Settling Zantac Cases for Up to $2.2 Billion
GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was contaminated with a suspected carcinogen.
GSK shares jump on $2.2 billion Zantac settlement
By Maggie Fick and Yamini Kalia (Reuters) -GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.
GSK settles vast majority of Zantac claims for $2.2 billion
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn remedy causes cancer
FTSE 100 Live 10 October: Index seen higher, GSK in $2.2bn Zantac settlement
GSK shares will be in focus today after it agreed a $2.2 billion settlement to resolve about 80,000 or 93% of court cases involving heartburn drug Zantac. The wider FTSE 100 index is seen about 17 points higher at 8261,
GSK shares seen opening higher after settlement of 80,000 Zantac lawsuits
Shares of GSK are seen rising 5% according to pre-market indications on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle lawsuits that claimed its discontinued heartburn drug Zantac caused cancer.
GSK Reaches $2.2 Bln Settlement Over Zantac Liability Cases
GSK plc (GSK, GSK.L) announced that it has reached agreements with 10 plaintiff firms representing approximately 93% (around 80,000)
9h
GlaxoSmithKline (GSK) Gets a Hold from Kepler Capital
In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
E&E
1d
How ‘green’ inhalers could evade Biden’s drug pricing legacy
AstraZeneca and
GlaxoSmithKline
produce some of the most widely used inhalers in the United States, including Symbicort and ...
NBC Los Angeles
1d
Cerebras IPO has ‘too much hair' as AI chipmaker tries to sell Wall Street on Nvidia alternative
Cerebras is playing in a huge market with insatiable investor demand, but its IPO prospectus is littered with red flags that ...
2d
Citi Keeps Their Buy Rating on GlaxoSmithKline (GSK)
Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...
5d
on MSN
How to Delete Your 23andme Data Amid the Company's Turmoil
DNA analysis company 23andme has been in trouble lately: data was breached in a 2023 hack, and this September the entire ...
3d
GlaxoSmithKline Pharma to enter oncology market, launch adult vax
GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...
policymed.com
6h
Pioneering Discussions at IISLD 2024: Advancing Treatment for PBC and Alpha-1 Antitrypsin Deficiency
This year's International Symposium on Liver Diseases (IISLD) 2024, held in the San Diego Convention Center, includes two key ...
2d
GlaxoSmithKline (GSK) Receives a Sell from J.P. Morgan
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
GSK
Zantac settlement
RSV vaccine
United States
Trade
Feedback